Introduction {#sec1-1}
============

The 1918 "Spanish flu" is one of the few examples of an infectious disease that has plagued humans and has prominently marked itself in history. More than a century now, infectious diseases are still the leading causes of disability, morbidity, and mortality worldwide.\[[@ref1][@ref2]\] In India too, high rate of infections is a public health threat which is not only associated with increased mortality rate, but also responsible for disability and prolonged hospital stay.\[[@ref3]\] The crude mortality rate in India is 417/100,000 persons.\[[@ref4]\] Over the years, the poor antimicrobial stewardship in India has led to an increase in multidrug-resistant (MDR) pathogens in both community and hospital settings.\[[@ref4][@ref5]\]

Gram-positive pathogens have played a crucial role in common infections such as sepsis, pneumonia, and urinary tract infections. *Staphylococcus aureus* is the major Gram-positive pathogen related to clinical infections ranging from bacteremia, skin and soft--tissue infections to device-related infections.\[[@ref6]\] Methicillin Resistant *S. aureus* (MRSA) is a life-threatening nosocomial pathogen whose resistance pattern is contributed by either multiple mutations or by horizontal gene transfer. Moreover, according to national guidelines on antimicrobial use, patients infected with MRSA have a high mortality rate\[[@ref7]\] which could be due to various factors such as late detection, manifestation of the underlying susceptibility to infections, and past antibiotic overuse. A recent multicentric study has reported the overall MRSA prevalence to be 37.3%;\[[@ref8]\] however, other studies have reported the prevalence to range from 20.2% to 80.4% depending on the geographical region.\[[@ref9][@ref10][@ref11][@ref12]\]

Apart from MRSA, another potential threat is the emergence of MDR enterococci, especially vancomycin-resistant enterococci (VRE). *Enterococcus* species consisting of *Enterococcus faecalis* and *Enterococcus* faecium are the most common causative pathogens of urinary tract infections followed by bloodstream infections (BSIs).\[[@ref13]\] Indian studies have shown VRE prevalence to vary from 1% to 9%, which has raised concerns for clinicians to treat difficult enterococcal infections in patients.\[[@ref14][@ref15][@ref16][@ref17]\] The shift in the antibiotic paradigm has, therefore, made it necessary to investigate the susceptibility pattern of Gram-positive pathogens in order to select an appropriate antibiotic regimen for patients with resistant pathogens. Therefore, the aim of this study is to investigate the prevalence and the antibiotic sensitivity pattern of Gram-positive pathogen in various infections in a tertiary care hospital in Mumbai.

Materials and Methods {#sec1-2}
=====================

This retrospective cross-sectional study was carried out from January, 2015 to December, 2017, at a tertiary care hospital in Mumbai, India. The patient samples were processed using standard laboratory techniques and were further cultured overnight on Columbia sheep blood agar (CBA) (BioMérieux, France) and on MacConkey\'s agar (HIMedia, India). After colony characterization and Gram staining, the Gram-positive pathogens were processed and distinguished on the basis of catalase test, slide coagulase test, and tube coagulase test. Further, organism identification and antibiotic susceptibility test was done using the automated VITEK 2 compact system (BioMérieux, France). For streptococci identification, CBA plates were inoculated and Kirby--Bauer disc diffusion testing was done. The antibiotic susceptibility testing was reported as per the Clinical and Laboratory Standards Institute criteria.\[[@ref18][@ref19]\]

Results {#sec1-3}
=======

Prevalence of Gram-positive isolates {#sec2-1}
------------------------------------

A total of 7393 bacterial isolates were analyzed from 2015 to 2017. Of the 2132 Gram-positive pool (29%), *S. aureus* (48.8%) formed the major encountered pathogen followed by *Enterococcus* spp. (24.6%) and coagulase-negative *Staphylococcus* (CoNS) (15.7%). [Table 1](#T1){ref-type="table"} summarizes the Gram-positive prevalence from 2015 to 2017.

###### 

Total prevalence of Gram-positive pathogens in our hospital

  Gram-positive pathogens   2015 (*n*=707)   2016 (*n*=711)   2017 (*n*=714)   Total prevalence (%)
  ------------------------- ---------------- ---------------- ---------------- ----------------------
  *Staphylococcus aureus*   361              338              342              48.8
  *Enterococcus* spp.       186              175              163              24.6
  CoNS                      81               123              131              15.7
  *Streptococcus* spp.      76               74               78               10.7

CoNS=Coagulase-negative *Staphylococcus*

Majority of *S. aureus* (61.2%) were isolated from patients with skin and soft-tissue infections (SSTIs) followed by respiratory infections (41.1%) and BSIs (35.1%). Out of the total Gram-positive pathogens, 310 (14.5%) were MRSA isolates. Further, the MRSA isolates formed 29.7% of the total *S. aureus* identified, whereas the total methicillin-sensitive *S. aureus* (MSSA) prevalence was 67.3% from 2015 to 2017. [Table 2](#T2){ref-type="table"} summarizes the MRSA prevalence from 2015 to 2017. [Table 3](#T3){ref-type="table"} summarises system wise infection prevalence of gram positive infections.

###### 

Total methicillin-resistant staphylococcus aureus and methicillin-susceptible staphylococcus aureus prevalence in Gram-positive isolates from 2015 to 2017

  Total Gram-positive isolates   2015 (*n*=707)   2016 (*n*=711)   2017 (*n*=714)   Total prevalence (%)
  ------------------------------ ---------------- ---------------- ---------------- ----------------------
  Total *S. aureus*              361              338              342              28.8
  MRSA                           124              81               105              29.7
  MSSA                           223              255              225              67.3

*S. aureus*=*Staphylococcus aureus*, MSSA=Methicillin-susceptible *S. aureus*, MRSA=Methicillin-resistant *S*. *aureus*

###### 

Total prevalence of *Staphylococcus aureus*, coagulase-negative *Staphylococcus, Streptococcus* spp., and *Enterococcus* spp.

  Pathogen               Infection       2015   2016   2017         Total prevalence (%)
  ---------------------- --------------- ------ ------ ------------ ----------------------
  *S. aureus*            BSI (*n*=435)   83     44     26           153 (35.10)
  SSTIs (*n*=1355)       262             268    300    830 (61.2)   
  RTI (*n*=68)           3               16     9      28 (41.1)    
  CoNS                   BSI (*n*=435)   51     64     58           173 (39.7)
  SSTIs (*n*=1355)       21              43     61     125 (9.2)    
  *Streptococcus* spp.   BSI (*n*=435)   26     20     10           56 (12.8)
  SSTIs (*n*=1355)       35              50     45     130 (9.6)    
  RTI (*n*=68)           13              3      16     32 (47)      
  *Enterococcus* spp.    BSI (*n*=435)   14     22     15           51 (11.7)
  SSTIs (*n*=1355)       93              88     86     267 (19.7)   
  UTI (*n*=175)          69              55     43     167 (95.4)   

CoNS=Coagulase-negative *Staphylococcus*, BSI=Bloodstream infection, SSTIs=Skin and soft-tissue infections, RTI=Respiratory tract infection, *S. aureus*=*Staphylococcus aureus*

Apart from *S. aureus*, the second most common infection in blood was caused by CoNS pathogens (39.7%). While 9.2% of the CoNS species were responsible for infection in patients with SSTIs, no role of these pathogens was observed in respiratory or urinary tract infections. Further, *Staphylococcus epidermidis* was the most common CoNS species in both BSI and SSTIs, representing 62.4% and 68% of the total CoNS species identified, respectively. *Staphylococcus haemolyticus* represented 12.4%. Other rare CoNS species identified included *Staphylococcus hominis* (6.5%), *Staphylococcus lugdunensis* (4.5%), *Staphylococcus warneri* (2%), *Staphylococcus xylosus* (1.5%), *Staphylococcus capitis* (1.2%), *Staphylococcus urealyticus* (\<1%), *Staphylococcus sciuri* (\<1%), and *Staphylococcus saprophyticus* (\<1%).

*Streptococcus* spp. were the most dominant pathogen isolated in patients with respiratory tract infection (RTI) (47%), whereas in BSI and SSTIs, it was 12.9% and 9.6%, respectively. While *Streptococcus pneumoniae* (37.5%) was the most common *Streptococcus* spp. in RTI patients, patients with BSI and SSTIs also had *Streptococcus pyogenes* (12.2%), *Streptococcus agalactiae* (10%), *Streptococcus mitis* (1.8%), *Streptococcus dys equisimilis* (\<1%), *Streptococcus anginosus* (\<1%), and *Streptococcus pasteurianus* (\<1%).

On the other hand, the total prevalence of *Enterococcus faecalis* was 30.8% while that of *E. faecium* was 8.4% of the total isolated *Enterococcus* species. In addition, *Enterococcus* spp. were the major causating pathogen behind urinary tract infections (95.4%), whereas only 19.7% and 11.7% were responsible for SSTIs and BSI, respectively.

Antibiotic sensitivity pattern in *Staphylococcus aureus* and *Enterococcus* spp. {#sec2-2}
---------------------------------------------------------------------------------

An antibiotic sensitivity pattern for ciprofloxacin, erythromycin, clindamycin, co-trimoxazole, linezolid, vancomycin, daptomycin, tigecycline, and teicoplanin was determined. MRSA isolates showed lower sensitivity toward ciprofloxacin (10.2%), erythromycin (24%), clindamycin (30.2%), and co-trimoxazole (39.2%) as compared to MSSA isolates \[[Figure 1](#F1){ref-type="fig"}\].

![Antibiotic sensitivity pattern in methicillin-resistant *Staphylococcus aureus* and methicillin-sensitive *Staphylococcus aureus* isolates](JLP-11-144-g001){#F1}

Further, MRSA was shown to be highly susceptible toward linezolid (98%), vancomycin (97.7%), and teicoplanin (98.3%). All MRSA and MSSA isolates tested were found to be sensitive to daptomycin and tigecycline (100%). Moreover, none of the isolates were found to be sensitive to benzyl penicillin.

We also investigated the sensitivity pattern in *Enterococcus* spp., where they were highly susceptible to linezolid (96%), vancomycin (92%), and teicoplanin (93.3%) while being resistant to erythromycin and ciprofloxacin. Further, the prevalence of VRE was found to be 7.5%. [Figure 2](#F2){ref-type="fig"} shows the sensitivity pattern for *Enterococcus* spp.

![Antibiotic sensitivity pattern of *Enterococcus* species](JLP-11-144-g002){#F2}

Discussion {#sec1-4}
==========

MDR bacterial infections have today become the biggest threat in the world due to the irrational use of antimicrobial agents. The European Prevalence of Infection in Intensive Care 2 study showed that, out of 47% of the Gram-positive isolates, 20% were *S. aureus* which was further associated with longer ICU stay.\[[@ref20]\] In India too, Gram-positive infections, particularly MRSA, have been reported to increase exponentially from 29% in 2009 to 47% in 2014.\[[@ref21]\] The overall MRSA prevalence in our study was 29.7%, which was lower than the recently reported prevalence of 37.3% by ICMR-AMRSN\[[@ref8]\] and 40% as reported by INSAR study.\[[@ref22]\] Furthermore, the prevalence varies among different centers across India ranging from 20.2% in Gujarat to 80.4% in Odisha. This variation could be attributed to the fact that different centers have different patient profiles and local antibiotic regimens that could influence the overall prevalence.

The ICMR-AMRSN study reported *S. aureus* to be the most frequently isolated organism in SSTI patients (73.7%).\[[@ref8][@ref23]\] Similarly, our study also showed similar results with *S. aureus* isolates to be 61.2% in SSTI patients. Further, we also report a high prevalence of *S. aureus* (35.1%) in BSI patients. Recently, apart from SSTIs, *S. aureus* has also emerged to be a critical pathogen in BSIs.\[[@ref24]\] This is further supported by a study conducted by Tak *et al*. where the crude mortality rate in patients with MRSA BSI was 31%.\[[@ref25]\]

In 2010, India was the highest antibiotic consumer, with 10.7 units being consumed per person. Among BRICS countries, India registered an increase of 23% in the retail sale volume.\[[@ref26]\] Therefore, easy availability and inappropriate antibiotic abuse has resulted in the development of antimicrobial resistance, which is difficult to treat and has become a national health disaster, today. In the present study, the MRSA isolates showed higher resistance toward ciprofloxacin, erythromycin, co-trimoxazole, and clindamycin as compared to MSSA isolates. Similar observations were also seen in previous multicentric studies.\[[@ref8][@ref22]\] These findings justify the increased mortality rates\[[@ref27]\] among patients infected with MRSA infections due to the ability of the pathogen to display varied resistance patterns toward various antibiotics. Moreover, both daptomycin and tigecycline remained the most effective antibiotics against *S. aureus* because there was no resistant isolate observed. This effect could be attributed to two reasons, with the higher cost of the drugs to be the primary reason due to which these drugs are not used very commonly. Second, both tigecycline and daptomycin are not the antibiotic of choice for treating BSIs and lung infections, both of which are the most common sources of infection in our hospital.

Vancomycin has been regarded as the first-line drug for the treatment of MRSA and MDR *Enterococcus* spp. Vancomycin was highly effective against MRSA isolates as we documented \<1% of vancomycin-intermediate strains in them. However, a meta-analysis has shown vancomycin-intermediate *S. aureus* (VISA) and hetero-VISA prevalence to be 15.09% and 12.41%, respectively.\[[@ref28]\] While we observed only three (\<1%) vancomycin-resistant isolates, a study by Singh *et al*. has reported 13% of VRSA isolates.\[[@ref29]\]

The first vancomycin-resistant *E. faecalis* and *E. faecium* was reported in 1988 in England.\[[@ref30]\] Subsequently, the first case of VRE was reported from New Delhi in 1999\[[@ref31]\] because of unscrupulous use of vancomycin for *Enterococcus* treatment. In India, the prevalence of VRE infection is increasing with every passing year. In 2003, the VRE prevalence was 1%\[[@ref14]\] which in 2013 has risen up to 8.7%.\[[@ref17]\] In the present study too, a total of 39 (7.5%) VRE isolates were obtained. Moreover, eight isolates (1.5%) of *E. gallinarum* and *E. casseliflavus*, which have inherent resistance to vancomycin, were also observed. However, out of the eight isolates, one isolate was vancomycin, linezolid, and teicoplanin resistant.

Linezolid is the only oral antibiotic available as compared to its other counterparts for the treatment of resistant Staphylococcus species. Furthermore, linezolid is used as a reserved drug for the treatment of difficult extremely drug-resistant tuberculosis and extensively drug-resistant tuberculosis.\[[@ref32]\] However, linezolid overuse in the management of Gram-positive pathogens, which are otherwise easy to treat, has caused an emergence of linezolid-resistant strains. Globally, there are not much reports about the prevalence of linezolid-resistant *S. aureus* (\<1%). A study from Rajasthan showed 12% of the linezolid-resistant *S. aureus*;\[[@ref33]\] however, we show that 98% of the MRSA isolates were sensitive to linezolid, making it a potent drug for activity against resistant Staphylococcus organisms. Further, in case of *Enterococcus*, linezolid is a successful therapeutic option if vancomycin treatment fails. Kumar *et al*. first reported linezolid-resistant enterococci (LRE) in 2014.\[[@ref34]\] However, there are no further reports which document the prevalence of LRE, thereby making this the first study to show a high LRE prevalence of 4.1%. The high prevalence of LRE in our hospital may have resulted due to the increased MRSA prevalence which further corresponds to an increase in the use of linezolid empirically. Due to this, the antimicrobial stewardship program in the hospital has taken measures and has tightened the program in order to keep a check on the increasing resistant strains.

Conclusion {#sec1-5}
==========

This study demonstrates MRSA and VRE as a growing health problem in India. While, vancomycin and linezolid remain the preferred choice for MRSA and multiresistant *Enterococcus* treatment, the rise in both vancomycin- and linezolid-resistant strains has caused treatment dilemmas for clinicians. Therefore, the data generated provide in-depth knowledge of the changing antibiotic regimen against the difficult pathogens, thereby helping the physicians to make the right antibiotic choice at the start of the treatment. Further, there is an urgent need for new research molecules to combat the difficult MDR pathogens.
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